The role of the platelet function analyser (PFA-100™) in the characterization of patients with von Willebrand's disease and its relationships with von Willebrand factor and the ABO blood group

被引:11
作者
Nitu-Whalley, IC
Lee, CA
Brown, SA
Riddell, A
Hermans, C
机构
[1] Royal Free UCL, Haemostasis Unit, London, England
[2] Royal Free UCL, Katherine Dormandy Haemophilia Ctr, London, England
关键词
ABO blood group; platelet function analyser; relationships; von Willebrand's disease; von Willebrand factor;
D O I
10.1046/j.1365-2516.2003.00755.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Determination of the closure time (CT) with the platelet function analyser (PFA-100(TM)) is a useful screening test for von Willebrand's disease (VWD) but its role in the characterization of VWD is not well established. We studied the relationship between the prolongation of the CT with adenosine diphosphate (ADP) (CT-ADP) and epinephrine (CT-EPI) cartridges and the von Willebrand factor (VWF) in 53 patients with VWD. We found that a relatively small percentage of the prolongation of the CT-ADR and CT-ADP (16 and 29%, respectively) was determined by a reduction in VWF levels. The CT-ADP was significantly more prolonged in the presence of qualitative defects in VWF but could not discriminate between the VWD subtypes. The ABO blood group had no effect on the prolongation of the CT or the bleeding time. In conclusion, the PFA-100(TM) appears of little use in the characterization of severity and subtype of VWD.
引用
收藏
页码:298 / 302
页数:5
相关论文
共 16 条
[1]   BLEEDING-TIME, BLOOD-GROUPS AND VONWILLEBRAND-FACTOR [J].
CAEKEBEKEPEERLINCK, KMJ ;
KOSTER, T ;
BRIET, E .
BRITISH JOURNAL OF HAEMATOLOGY, 1989, 73 (02) :217-220
[2]  
Cattaneo M, 1999, THROMB HAEMOSTASIS, V82, P35
[3]   Utility of the PFA-100® for assessing bleeding disorders and monitoring therapy:: a review of analytical variables, benefits and limitations [J].
Favaloro, EJ .
HAEMOPHILIA, 2001, 7 (02) :170-179
[4]   Screening for von Willebrand disease with a new analyzer using high shear stress: A study of 60 cases [J].
Fressinaud, E ;
Veyradier, A ;
Truchaud, F ;
Martin, I ;
Boyer-Neumann, C ;
Trossaert, M ;
Meyer, D .
BLOOD, 1998, 91 (04) :1325-1331
[5]   Therapeutic monitoring of von Willebrand disease: interest and limits of a platelet function analyser at high shear rates [J].
Fressinaud, E ;
Veyradier, A ;
Sigaud, M ;
Boyer-Neumann, C ;
Le Boterff, C ;
Meyer, D .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (03) :777-783
[6]  
GILL JC, 1987, BLOOD, V69, P1691
[7]   Performance of the platelet function analyser PFA-100® in testing abnormalities of primary haemostasis [J].
Harrison, P ;
Robinson, MSC ;
Mackie, IJ ;
Joseph, J ;
McDonald, SJ ;
Liesner, R ;
Savidge, GF ;
Pasi, J ;
Machin, SJ .
BLOOD COAGULATION & FIBRINOLYSIS, 1999, 10 (01) :25-31
[8]   A revised model of platelet aggregation [J].
Kulkarni, S ;
Dopheide, SM ;
Yap, CL ;
Ravanat, C ;
Freund, M ;
Mangin, P ;
Heel, KA ;
Street, A ;
Harper, IS ;
Lanza, F ;
Jackson, SP .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (06) :783-791
[9]  
Lasne D, 2000, THROMB HAEMOSTASIS, V84, P794
[10]  
Lippi G, 2001, THROMB HAEMOSTASIS, V85, P369